BMI View: Argentina's pharmaceutical industry has been relatively competitive in the Latin America
region due to skilled professionals, low-cost operations and export-oriented policies. However, public
incentives in the Argentinean biotechnology sector remain scant, a ..."
BMI View: Domestic pharmaceutical companies in Argentina are more competitive than many other Latin
American drugmakers. Unlike neighbouring country Brazil, which can lure multinationals to supply
advanced technologies in exchange for a secure market share in its attr ..."
BMI View: High inflation and the potential currency devaluation will continue to erode foreign
pharmaceutical companies' profitability in Argentina's drug market. Furthermore, the lack of data
protection and unorthodox import regulations are yet to be addressed by the local aut ..."
BMI View: High inflation has undermined foreign drugmakers' profitability in Argentina's pharmaceutical market. The potential currency devaluation will further erode the returns of foreign investment. Nevertheless, some multinationals continue to invest in the country, as its mar ..."
Argentina's pharmaceutical market will become increasingly unattractive to multinational pharmaceutical companies, as the double-digit market growth has been mainly driven by the high inflation rate. The strict currency and import restrictions, as well as poor regulatory regime, ..."